OrthoPediatrics (NASDAQ:KIDS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OrthoPediatrics (NASDAQ:KIDS) from a sell rating to a hold rating in a research report released on Saturday.

KIDS has been the topic of a number of other research reports. Canaccord Genuity Group initiated coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday, October 8th. Piper Sandler reduced their price objective on shares of OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Stifel Nicolaus decreased their price objective on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a report on Friday, October 10th. Finally, BTIG Research reiterated a “buy” rating and set a $23.00 target price on shares of OrthoPediatrics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

OrthoPediatrics Trading Down 1.9%

KIDS opened at $18.35 on Friday. The stock has a market capitalization of $460.22 million, a P/E ratio of -9.41 and a beta of 1.09. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $27.60. The firm’s fifty day simple moving average is $17.89 and its 200 day simple moving average is $18.96.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $61.25 million for the quarter, compared to the consensus estimate of $63.63 million. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%. As a group, research analysts anticipate that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock worth $17,813,000 after acquiring an additional 10,927 shares during the last quarter. Millennium Management LLC lifted its holdings in OrthoPediatrics by 20.8% during the 3rd quarter. Millennium Management LLC now owns 943,655 shares of the company’s stock valued at $17,486,000 after purchasing an additional 162,628 shares during the last quarter. Marshall Wace LLP boosted its position in OrthoPediatrics by 6.0% during the third quarter. Marshall Wace LLP now owns 444,320 shares of the company’s stock worth $8,233,000 after purchasing an additional 25,191 shares during the period. Prosight Management LP increased its holdings in shares of OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock valued at $5,720,000 after purchasing an additional 235,060 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.